An important role for Cholecystokinin, a CLOCK target gene, in the development and treatment of manic-like behaviors

R. N. Arey; J. F. Enwright; S. M. Spencer; E. Falcon; A. R. Ozburn; S. Ghose; C. Tamminga; C. A. Mcclung

doi:10.1038/mp.2013.12

An important role for Cholecystokinin, a CLOCK target gene, in the development and treatment of manic-like behaviors

R. N. Arey, J. F. Enwright, S. M. Spencer, E. Falcon, A. R. Ozburn, S. Ghose, C. Tamminga, C. A. Mcclung

Research output: Contribution to journal › Article › peer-review

38 Scopus citations

Abstract

Mice with a mutation in the Clock gene (ClockΔ19) have been identified as a model of mania; however, the mechanisms that underlie this phenotype, and the changes in the brain that are necessary for lithium's effectiveness on these mice remain unclear. Here, we find that cholecystokinin (Cck) is a direct transcriptional target of CLOCK and levels of Cck are reduced in the ventral tegmental area (VTA) of ClockΔ19 mice. Selective knockdown of Cck expression via RNA interference in the VTA of wild-type mice produces a manic-like phenotype. Moreover, chronic treatment with lithium restores Cck expression to near wild-type and this increase is necessary for the therapeutic actions of lithium. The decrease in Cck expression in the ClockΔ19 mice appears to be due to a lack of interaction with the histone methyltransferase, MLL1, resulting in decreased histone H3K4me3 and gene transcription, an effect reversed by lithium. Human postmortem tissue from bipolar subjects reveals a similar increase in Cck expression in the VTA with mood stabilizer treatment. These studies identify a key role for Cck in the development and treatment of mania, and describe some of the molecular mechanisms by which lithium may act as an effective antimanic agent.

Original language	English (US)
Pages (from-to)	342-350
Number of pages	9
Journal	Molecular psychiatry
Volume	19
Issue number	3
DOIs	https://doi.org/10.1038/mp.2013.12
State	Published - Mar 2014
Externally published	Yes

Bibliographical note

Funding Information:
We are grateful to Dr Joe Takahashi for the ClockD19 mice. We thank Elizabeth Gordon and Ariel Ketcherside for assistance with mouse husbandry and genotyping, Dr Shari Birnbaum and Ami Petterson for assistance with behavioral testing, and Dr Shibani Mukherjee for assistance with AAV construction and design. We also thank Dr Syann Lee and Dr Joel Elmquist for assistance with laser capture equipment. We also thank Dr R Jude Samulski and the UNC Gene Therapy Vector Core for assistance with AAV preparation. This study was funded by The McKnight Endowment Fund for Neuroscience, The Brain & Behavior Research Foundation (NARSAD) and the NIMH (MH082876).

Keywords

Bipolar disorder
Chromatin structure
Dopamine
Gene expression
Lithium

Access

10.1038/mp.2013.12

OpenUrl availability

Full text

Cite this

@article{b0b2397cabd94533b7c9856c4f5ce937,

title = "An important role for Cholecystokinin, a CLOCK target gene, in the development and treatment of manic-like behaviors",

abstract = "Mice with a mutation in the Clock gene (ClockΔ19) have been identified as a model of mania; however, the mechanisms that underlie this phenotype, and the changes in the brain that are necessary for lithium's effectiveness on these mice remain unclear. Here, we find that cholecystokinin (Cck) is a direct transcriptional target of CLOCK and levels of Cck are reduced in the ventral tegmental area (VTA) of ClockΔ19 mice. Selective knockdown of Cck expression via RNA interference in the VTA of wild-type mice produces a manic-like phenotype. Moreover, chronic treatment with lithium restores Cck expression to near wild-type and this increase is necessary for the therapeutic actions of lithium. The decrease in Cck expression in the ClockΔ19 mice appears to be due to a lack of interaction with the histone methyltransferase, MLL1, resulting in decreased histone H3K4me3 and gene transcription, an effect reversed by lithium. Human postmortem tissue from bipolar subjects reveals a similar increase in Cck expression in the VTA with mood stabilizer treatment. These studies identify a key role for Cck in the development and treatment of mania, and describe some of the molecular mechanisms by which lithium may act as an effective antimanic agent.",

keywords = "Bipolar disorder, Chromatin structure, Dopamine, Gene expression, Lithium",

author = "Arey, {R. N.} and Enwright, {J. F.} and Spencer, {S. M.} and E. Falcon and Ozburn, {A. R.} and S. Ghose and C. Tamminga and Mcclung, {C. A.}",

note = "Funding Information: We are grateful to Dr Joe Takahashi for the ClockD19 mice. We thank Elizabeth Gordon and Ariel Ketcherside for assistance with mouse husbandry and genotyping, Dr Shari Birnbaum and Ami Petterson for assistance with behavioral testing, and Dr Shibani Mukherjee for assistance with AAV construction and design. We also thank Dr Syann Lee and Dr Joel Elmquist for assistance with laser capture equipment. We also thank Dr R Jude Samulski and the UNC Gene Therapy Vector Core for assistance with AAV preparation. This study was funded by The McKnight Endowment Fund for Neuroscience, The Brain & Behavior Research Foundation (NARSAD) and the NIMH (MH082876).",

year = "2014",

month = mar,

doi = "10.1038/mp.2013.12",

language = "English (US)",

volume = "19",

pages = "342--350",

journal = "Molecular psychiatry",

issn = "1359-4184",

publisher = "Nature Publishing Group",

number = "3",

}

TY - JOUR

T1 - An important role for Cholecystokinin, a CLOCK target gene, in the development and treatment of manic-like behaviors

AU - Arey, R. N.

AU - Enwright, J. F.

AU - Spencer, S. M.

AU - Falcon, E.

AU - Ozburn, A. R.

AU - Ghose, S.

AU - Tamminga, C.

AU - Mcclung, C. A.

N1 - Funding Information: We are grateful to Dr Joe Takahashi for the ClockD19 mice. We thank Elizabeth Gordon and Ariel Ketcherside for assistance with mouse husbandry and genotyping, Dr Shari Birnbaum and Ami Petterson for assistance with behavioral testing, and Dr Shibani Mukherjee for assistance with AAV construction and design. We also thank Dr Syann Lee and Dr Joel Elmquist for assistance with laser capture equipment. We also thank Dr R Jude Samulski and the UNC Gene Therapy Vector Core for assistance with AAV preparation. This study was funded by The McKnight Endowment Fund for Neuroscience, The Brain & Behavior Research Foundation (NARSAD) and the NIMH (MH082876).

PY - 2014/3

Y1 - 2014/3

N2 - Mice with a mutation in the Clock gene (ClockΔ19) have been identified as a model of mania; however, the mechanisms that underlie this phenotype, and the changes in the brain that are necessary for lithium's effectiveness on these mice remain unclear. Here, we find that cholecystokinin (Cck) is a direct transcriptional target of CLOCK and levels of Cck are reduced in the ventral tegmental area (VTA) of ClockΔ19 mice. Selective knockdown of Cck expression via RNA interference in the VTA of wild-type mice produces a manic-like phenotype. Moreover, chronic treatment with lithium restores Cck expression to near wild-type and this increase is necessary for the therapeutic actions of lithium. The decrease in Cck expression in the ClockΔ19 mice appears to be due to a lack of interaction with the histone methyltransferase, MLL1, resulting in decreased histone H3K4me3 and gene transcription, an effect reversed by lithium. Human postmortem tissue from bipolar subjects reveals a similar increase in Cck expression in the VTA with mood stabilizer treatment. These studies identify a key role for Cck in the development and treatment of mania, and describe some of the molecular mechanisms by which lithium may act as an effective antimanic agent.

AB - Mice with a mutation in the Clock gene (ClockΔ19) have been identified as a model of mania; however, the mechanisms that underlie this phenotype, and the changes in the brain that are necessary for lithium's effectiveness on these mice remain unclear. Here, we find that cholecystokinin (Cck) is a direct transcriptional target of CLOCK and levels of Cck are reduced in the ventral tegmental area (VTA) of ClockΔ19 mice. Selective knockdown of Cck expression via RNA interference in the VTA of wild-type mice produces a manic-like phenotype. Moreover, chronic treatment with lithium restores Cck expression to near wild-type and this increase is necessary for the therapeutic actions of lithium. The decrease in Cck expression in the ClockΔ19 mice appears to be due to a lack of interaction with the histone methyltransferase, MLL1, resulting in decreased histone H3K4me3 and gene transcription, an effect reversed by lithium. Human postmortem tissue from bipolar subjects reveals a similar increase in Cck expression in the VTA with mood stabilizer treatment. These studies identify a key role for Cck in the development and treatment of mania, and describe some of the molecular mechanisms by which lithium may act as an effective antimanic agent.

KW - Bipolar disorder

KW - Chromatin structure

KW - Dopamine

KW - Gene expression

KW - Lithium

UR - http://www.scopus.com/inward/record.url?scp=84894515967&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84894515967&partnerID=8YFLogxK

U2 - 10.1038/mp.2013.12

DO - 10.1038/mp.2013.12

M3 - Article

C2 - 23399917

AN - SCOPUS:84894515967

SN - 1359-4184

VL - 19

SP - 342

EP - 350

JO - Molecular psychiatry

JF - Molecular psychiatry

IS - 3

ER -

An important role for Cholecystokinin, a CLOCK target gene, in the development and treatment of manic-like behaviors

Abstract

Bibliographical note

Keywords

Access

OpenUrl availability

Other files and links

Fingerprint

Cite this